¼¼°èÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀå
Medullary Thyroid Cancer
»óǰÄÚµå : 1794454
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 281 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀåÀº 2030³â±îÁö 22¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 22¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¿Ü°ú Ä¡·á´Â CAGR 8.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹æ»ç¼± Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 3¾ï 8,330¸¸ ´Þ·¯, Áß±¹Àº CAGR 12.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀåÀº 2024³â¿¡ 3¾ï 8,330¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀ» 12.1%·Î, 2030³â±îÁö 4¾ï 6,800¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.7%¿Í 7.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°©»ó¼± ¾Ç¼º Á¾¾ç Áß °©»ó¼± ¼öÁú¾ÏÀÌ µ¶Æ¯ÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°©»ó¼± ¼öÁú¾Ï(MTC)Àº °©»ó¼± ¾Ç¼ºÁ¾¾ç Áß¿¡¼­µµ µ¶Æ¯ÇÏ°í ºñ±³Àû µå¹® ÇüÅ·Î, Àü ¼¼°è °©»ó¼±¾Ï ¹ß»ýÀÇ ¾à 3-4%¸¦ Â÷ÁöÇÕ´Ï´Ù. ¿©Æ÷¼¼Æ÷¿¡¼­ ¹ß»ýÇÏ´Â ÀϹÝÀûÀÎ °©»ó¼± À¯µÎ¾ÏÀ̳ª ¿©Æ÷¾Ï°ú ´Þ¸®, MTC´Â Ä®½ÃÅä´ÑÀ̶ó´Â È£¸£¸óÀ» »ý»êÇÏ´Â ¿©Æ÷ÁÖÀ§ C¼¼Æ÷¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µ¶Æ¯ÇÑ ±â¿ø¿¡ µû¶ó MTC´Â »ý¹°ÇÐÀû °Åµ¿, ÀÓ»ó ¾ç»ó, Ä¡·á Á¢±Ù¹ýÀÌ ´Ù¸¨´Ï´Ù. MTC´Â »ê¹ßÀûÀ¸·Î ¶Ç´Â ´Ù¹ß¼º ³»ºÐºñÁ¾¾ç 2Çü(MEN2)°ú °°Àº À¯Àü¼º ÁõÈıºÀÇ ÀϺηΠ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î À¯ÀüÀÚ °Ë»ç´Â Áø´Ü ¹× À§Çèµµ ºÐ·ùÀÇ ÇÙ½ÉÀÔ´Ï´Ù. Ä®½ÃÅä´Ñ ¼öÄ¡¿Í Ä®½ÃÅä´Ñ Ç׿ø(CEA) ¼öÄ¡ÀÇ »ó½ÂÀº Á¶±â ¹ß°ß ¹× Áúº´ ¸ð´ÏÅ͸µÀ» À§ÇÑ Áß¿äÇÑ ¹ÙÀÌ¿À¸¶Ä¿°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ºÐÈ­Çü °©»ó¼±¾Ï°ú ´Þ¸® MTC´Â ÀϹÝÀûÀ¸·Î ¹æ»ç¼º ¿ä¿Àµå¸¦ Èí¼öÇÏÁö ¾Ê±â ¶§¹®¿¡ ±âÁ¸ °©»ó¼±¾Ï Ä¡·áÀÇ È¿°ú¸¦ Á¦ÇÑÇÕ´Ï´Ù. °©»ó¼± ÀüÀýÁ¦¼ú°ú ¸²ÇÁÀý ÀýÁ¦¼úÀ» µ¿¹ÝÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±×·¯³ª ÀÌ ÁúȯÀº Á¶±â ¸²ÇÁÀý ÀüÀÌ¿Í ¿ø°Ý ÀüÀÌ, ƯÈ÷ °£°ú Æó·Î ÀüÀ̵DZ⠽±±â ¶§¹®¿¡ Àå±âÀûÀÎ °ü¸®°¡ º¹ÀâÇØÁý´Ï´Ù. ¶ÇÇÑ À¯Àü¼º ȯÀÚ´Â ÀþÀº ³ªÀÌ¿¡ ¹ßº´ÇÏ´Â °æ¿ì°¡ ¸¹°í, ´Ù¸¥ ³»ºÐºñ Á¾¾çÀÌ ¹ß»ýÇÒ °¡´É¼ºµµ ÀÖÀ¸¹Ç·Î ÀÓ»óÀû º¹À⼺ÀÌ ´õ¿í Áõ°¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé·Î ÀÎÇØ MTC´Â Á¶±â Áø´Ü, ȯÀÚ °³°³Àο¡ ¸Â´Â Ä¡·á Àü·«, Æò»ý ¸ð´ÏÅ͸µÀÇ Çʿ伺ÀÌ °­Á¶µÇ¸ç, ÀÓ»óÀûÀ¸·Î °ü¸®Çϱ⠰¡Àå ¾î·Á¿î °©»ó¼±¾Ï Áß ÇϳªÀÔ´Ï´Ù.

ºÐÀÚ»ý¹°Çаú À¯ÀüÀÚ °Ë»çÀÇ ¹ßÀüÀº Áø´Ü°ú À§Çè Æò°¡¿¡ ¾î¶² º¯È­¸¦ °¡Á®¿À°í Àִ°¡?

ºÐÀÚ»ý¹°ÇÐ ¹× À¯ÀüÀÚ °Ë»çÀÇ ¹ßÀüÀ¸·Î °©»ó¼± ¼öÁú¾Ï¿¡ ´ëÇÑ ÀÌÇØ°¡ Å©°Ô Çâ»óµÇ¾î Áø´Ü°ú À§Çèµµ Æò°¡¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ƯÈ÷ MEN 2A¿Í MEN 2B¿Í °°Àº °¡Á·¼º ÁõÈıº°ú °ü·ÃµÈ »ç·Ê¿¡¼­ RET ¿ø À¯ÀüÀÚ µ¹¿¬º¯À̰¡ È®ÀÎµÈ °ÍÀº ȹ±âÀûÀÎ ¹ßÀüÀ̾ú½À´Ï´Ù. À§Ç豺¿¡ ´ëÇÑ À¯ÀüÀÚ °Ë»ç¸¦ ÅëÇØ Á¶±â ¹ß°ß ¹× ¿¹¹æÀû °©»ó¼± ÀýÁ¦¼úÀ» ½ÃÇàÇÒ ¼ö ÀÖÀ¸¸ç, À̸¦ ÅëÇØ »ýÁ¸À²À» ȹ±âÀûÀ¸·Î °³¼±ÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ü¼¼Æ÷ RET µ¹¿¬º¯ÀÌ¿Í RAS µ¹¿¬º¯ÀÌ´Â Á¾¾ç °Åµ¿°ú ÀáÀçÀû Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ȯÀÚ¸¦ °èÃþÈ­ÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó Ä¡·á Á¢±Ù ¹æ½Ä°ú ÈÄ¼Ó Á¶Ä¡ ÇÁ·ÎÅäÄÝÀ» º¸´Ù °³º°È­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ºÐÀÚÁø´Ü¹ýÀº ¶ÇÇÑ ±âÁ¸ÀÇ ¿µ»ó Áø´ÜÀ̳ª ¼¼Æ÷°Ë»ç·Î °á·ÐÀ» ³»¸± ¼ö ¾ø´Â °æ¿ì, °©»ó¼± °áÀýÀÇ ¾ç¼º°ú ¾Ç¼ºÀ» ½±°Ô °¨º°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾×ü»ý°Ë¹ýÀº ¾ÆÁ÷ ½ÃÀÛ ´Ü°è¿¡ ºÒ°úÇÏÁö¸¸, ºñħ½ÀÀûÀ¸·Î Áúº´ÀÇ ÁøÇà°ú Àç¹ßÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ À¯¸Á ¹æ¹ýÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ºÐÀÚ»ý¹°ÇÐÀû Áö½ÄÀº Ä®½ÃÅä´ÑÀ̳ª CEA¿Í °°Àº Ç÷û ¹ÙÀÌ¿À¸¶Ä¿¿¡ ÀÇÇØ º¸¿ÏµË´Ï´Ù. ¶ÇÇÑ À¯Àü»ó´ãÀº À¯Àü¼º MTC ȯÀÚ Ä¡·á¿¡ ÀÖÀ¸¸ç, Áß¿äÇÑ ¿ä¼Ò·Î °¡Á· Àüü¿¡ ´ëÇÑ À§Çè Æò°¡¿Í ¿¹¹æ Àü·«À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¤¹ÐÀÇÇÐÀÌ °è¼Ó ¹ßÀüÇϰí ÀÖ´Â °¡¿îµ¥, À¯ÀüÇÐÀû ¹× ºÐÀÚÇÐÀû µ¥ÀÌÅÍÀÇ ÅëÇÕÀº Áø´Ü Á¤È®µµ¸¦ ´õ¿í Çâ»ó½Ã۰í, °ø°ÝÀûÀÎ °©»ó¼±¾Ï ȯÀÚÀÇ °³º°È­µÈ °ü¸®¸¦ °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Ä¡·á »óȲÀÇ º¯È­¿¡¼­ Ç¥ÀûÄ¡·áÁ¦¿Í ½Å¾àÀº ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

°©»ó¼± ¼öÁú¾ÏÀÇ Ä¡·á »óȲÀº Ç¥Àû Ä¡·á¿Í ½Å¾à °³¹ßÀÇ ÃâÇöÀ¸·Î ¿ÏÀüÈ÷ ¹Ù²î¾ú½À´Ï´Ù. ÁøÇ༺, ¼ö¼ú ºÒ°¡´É ¶Ç´Â ÀüÀ̼º MTC ȯÀÚÀÇ °æ¿ì, ±âÁ¸ÀÇ È­Çпä¹ýÀ̳ª ¹æ»ç¼± Ä¡·á´Â È¿°ú¿¡ ÇѰ谡 ÀÖÀ¸¸ç, º¸´Ù È¿°úÀûÀÎ Àü½Å Ä¡·á¹ýÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ¹Ýµ¥Å¸´Õ, Ä«º¸ÀÜÆ¼´Õ°ú °°Àº Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦(TKI)´Â ÀÌ·¯ÇÑ °æ¿ì, ƯÈ÷ ÁøÇ༺ ȯÀÚµéÀ» À§ÇÑ ÃÖÀü¼± Ä¡·áÁ¦·Î µîÀåÇß½À´Ï´Ù. ÀÌµé ¾àÁ¦´Â RET ¹× Á¾¾ç ¼ºÀå°ú Ç÷°ü½Å»ý¿¡ °ü¿©ÇÏ´Â ´Ù¸¥ °æ·Î¸¦ ¾ïÁ¦ÇÏ¿© ¹«ÁøÇà»ýÁ¸±â°£ ¿¬Àå ¹× º´¼¼ Á¶ÀýÀ» °¡Á®¿É´Ï´Ù. ÃÖ±Ù¿¡´Â ¼¿·çÆä¸£Æ¼´ÕÀ̳ª ÇÁ¶ö¼¼Æ¼´Õ°ú °°Àº °í¼±ÅÃÀû RET ¾ïÁ¦Á¦°¡ ƯÈ÷ RET µ¹¿¬º¯ÀÌ Á¾¾ç ȯÀÚ¿¡¼­ Ç¥Àû ¿Ü È¿°ú°¡ ÀûÀº À¯ÀǹÌÇÑ ÀÓ»óÀû È¿°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº Á¤¹Ð Á¾¾çÇп¡¼­ Áß¿äÇÑ ÁøÀüÀ̸ç, ÀÓ»óÀǰ¡ ȯÀÚÀÇ Æ¯Á¤ À¯ÀüÀû º¯È­¿¡ ¸Â°Ô Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ°Ô ÇØÁֱ⠶§¹®ÀÔ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡¼­´Â ÇöÀç Ä¡·áÁ¦¿¡ ´ëÇÑ ³»¼ºÀ» ±Øº¹Çϱâ À§ÇÑ º´¿ë¿ä¹ý, ¸é¿ª¿ä¹ý, ±âŸ »õ·Î¿î ¾àÁ¦µéÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí Ä¡·áÀÇ ºÎÀÛ¿ë°ú ÃÖÁ¾ÀûÀÎ Áúº´ ÁøÇàÀÇ À§ÇèÀº ¿©ÀüÈ÷ °úÁ¦À̸ç, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Ä¡·á Àü·«ÀÇ Á¶Á¤ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀº ÀÇ·á ÀÎÇÁ¶ó¿Í º¸Çè Àû¿ë ¹üÀ§¿¡ µû¶ó ´Þ¶óÁú ¼ö ÀÖÀ¸¸ç, Áö¿ª¿¡ µû¶ó Ä¡·á °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¿¬±¸·Î ÀÎÇØ Ç¥ÀûÄ¡·áÁ¦°¡ È®´ëµÇ¸é¼­ ÁøÇ༺ MTC ȯÀÚÀÇ Àü¸ÁÀº °³¼±µÇ°í ÀÖÁö¸¸, Àå±âÀûÀÎ °ü¸®¸¦ À§Çؼ­´Â À¯È¿¼º, ¾ÈÀü¼º, QOLÀÇ ±ÕÇüÀ» ½ÅÁßÇÏ°Ô °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

°©»ó¼± ¼öÁú¾Ï ½ÃÀåÀÇ ¼ºÀå°ú Çõ½ÅÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

°©»ó¼± ¼öÁú¾Ï ½ÃÀåÀÇ ¼ºÀåÀº Áø´Ü ±â¼ú Çõ½Å, ÀǾàǰ °³¹ß, ȯÀÚ ÀÎ½Ä °³¼±, ÀÇ·á ÀÎÇÁ¶ó È®Ãæ°ú °ü·ÃµÈ ¿©·¯ °¡Áö ÈûÀÌ ±³Â÷Çϸ鼭 ÀÌ·ç¾îÁý´Ï´Ù. ù°, Á¤±âÀûÀÎ °æºÎ ÃÊÀ½ÆÄ °Ë»ç¿Í ¼¼Ä§ÈíÀÔ »ý°ËÀÇ º¸±ÞÀ¸·Î °©»ó¼± °áÀýÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁ³°í, ±× Áß ÀϺδ ÈÄ¼Ó ºÐÀÚ »ýÈ­ÇÐ °Ë»ç¸¦ ÅëÇØ MTC·Î È®Àε˴ϴÙ. µÑ°, MEN 2¿Í °°Àº À¯Àü¼º ÁõÈıº¿¡ ´ëÇÑ ÀÇ»ç¿Í ÀϹÝÀÎÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ À¯Àü »ó´ã°ú °íÀ§Ç豺 °¡Á·¿¡ ´ëÇÑ Á¶±â °ËÁø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Â°, À¯ÀüüÇаú Á¤¹ÐÀÇ·áÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀº »ýÁ¸ ¿¹Èĸ¦ °³¼±Çϰí ÁøÇ༺ Áúȯ ȯÀÚ¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» Áִ ǥÀûÄ¡·áÁ¦ °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ³Ý°, Á¦¾à»çµéÀÇ Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ MTC¿Í °°Àº Èñ±Í¾Ï Ä¡·áÁ¦ÀÇ ¿¬±¸¿Í »ó¿ëÈ­¸¦ ÃËÁøÇÏ¿© º¸´Ù źźÇÑ Ä¡·á ÆÄÀÌÇÁ¶óÀÎÀ» ¸¸µé¾î³»°í ÀÖ½À´Ï´Ù. ´Ù¼¸Â°, µðÁöÅÐ Çコ Åø°ú ȯÀÚ Áö¿ø Ç÷§ÆûÀÇ º¸±ÞÀ¸·Î ¼¼ÄÁµå ¿ÀÇǴϾ𿡠´ëÇÑ Á¢±Ù, ÀÓ»ó½ÃÇè Âü¿©, ´õ ³ªÀº Ä¡·á °ü¸®°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¿©¼¸Â°, ½ÅÈï ±¹°¡ÀÇ ÀÇ·á Á¢±Ù¼ºÀÌ È®´ëµÇ¸é¼­ °ÝÂ÷´Â ¿©ÀüÈ÷ Á¸ÀçÇÏÁö¸¸, Áø´ÜÀ²°ú Ä¡·áÀ²ÀÌ Á¡Â÷ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Àϰö°, ÆÐ½ºÆ®Æ®·¢ ÁöÁ¤°ú Èñ±ÍÁúȯ Ä¡·áÁ¦ ½ÂÀÎÀ» ÅëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀ¸·Î »õ·Î¿î Ä¡·áÁ¦°¡ Ãâ½ÃµÇ´Â ½Ã°£ÀÌ »¡¶óÁö°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ³»ºÐºñÇÐ, Á¾¾çÇÐ, À¯ÀüÇÐ, ¿Ü°ú¸¦ ÅëÇÕÇÑ ´ÙÇÐÁ¦Àû Ä¡·á ¸ðµ¨Àº Çùµ¿ÀûÀ̰í Á¾ÇÕÀûÀÎ Ä¡·á¸¦ ÅëÇØ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ÀüüÀûÀ¸·Î °©»ó¼± ¼öÁú¾Ï ȯÀÚÀÇ Áø´Ü, Ä¡·á ¹× »îÀÇ Áú Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃá ¼ºÀåÇϰí Á¡Á¡ ´õ Á¤±³ÇØÁö´Â ½ÃÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á(¿Ü°ú Ä¡·á, ¹æ»ç¼± Ä¡·á, È­Çпä¹ý Ä¡·á); ÃÖÁ¾ ¿ëµµ(º´¿ø, ¹æ»ç¼± Ä¡·á ¼¾ÅÍ, ¾Ï¿¬±¸±â°ü)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¿¡ Äõ¸® ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Medullary Thyroid Cancer Market to Reach US$2.2 Billion by 2030

The global market for Medullary Thyroid Cancer estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.3 Million While China is Forecast to Grow at 12.1% CAGR

The Medullary Thyroid Cancer market in the U.S. is estimated at US$383.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$468.0 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Medullary Thyroid Cancer Market - Key Trends & Drivers Summarized

What Makes Medullary Thyroid Cancer Unique Among Thyroid Malignancies?

Medullary thyroid cancer (MTC) stands out as a distinct and relatively rare form of thyroid malignancy, accounting for approximately 3 to 4 percent of all thyroid cancer cases worldwide. Unlike the more common papillary and follicular thyroid cancers, which originate from follicular cells, MTC arises from parafollicular C cells that produce the hormone calcitonin. This unique origin gives MTC a different biological behavior, clinical presentation, and treatment approach. MTC can occur sporadically or as part of inherited syndromes such as multiple endocrine neoplasia type 2 (MEN 2), making genetic testing a cornerstone of diagnosis and risk stratification. The presence of elevated calcitonin and carcinoembryonic antigen (CEA) levels serves as important biomarkers for early detection and disease monitoring. Unlike differentiated thyroid cancers, MTC does not typically absorb radioactive iodine, limiting the effectiveness of traditional thyroid cancer therapies. Surgical resection remains the primary curative intervention, often involving total thyroidectomy and lymph node dissection. However, the disease’s propensity for early lymphatic spread and distant metastasis, especially to the liver and lungs, complicates long-term management. Additionally, patients with inherited forms often present at a younger age and may develop other endocrine tumors, further increasing clinical complexity. These factors underscore the need for early diagnosis, tailored treatment strategies, and lifelong monitoring, making MTC one of the most challenging thyroid cancers to manage clinically.

How Are Advances in Molecular Biology and Genetic Testing Reshaping Diagnosis and Risk Assessment?

The understanding of medullary thyroid cancer has been significantly enhanced by advances in molecular biology and genetic testing, which have become integral to both diagnosis and risk assessment. The identification of mutations in the RET proto-oncogene has been a landmark development, particularly in cases associated with familial syndromes such as MEN 2A and MEN 2B. Genetic screening of at-risk individuals allows for early detection and prophylactic thyroidectomy, which has been shown to dramatically improve survival outcomes. In sporadic cases, somatic RET mutations and RAS mutations offer insights into tumor behavior and potential therapeutic responses. The ability to stratify patients based on their genetic profiles has led to more personalized treatment approaches and follow-up protocols. Molecular diagnostics also facilitate differentiation between benign and malignant thyroid nodules when traditional imaging and cytology are inconclusive. Liquid biopsy techniques, though still emerging, show promise for non-invasive monitoring of disease progression and recurrence. These molecular insights are complemented by serum biomarkers such as calcitonin and CEA, which serve as reliable indicators of tumor burden and treatment response. Furthermore, genetic counseling has become a critical component of care for patients with hereditary forms of MTC, allowing for family-wide risk assessment and preventive strategies. As precision medicine continues to evolve, the integration of genetic and molecular data is expected to further refine diagnostic accuracy and improve individualized management for patients with this aggressive form of thyroid cancer.

What Role Do Targeted Therapies and Novel Drugs Play in Changing the Treatment Landscape?

The treatment landscape for medullary thyroid cancer has undergone a transformative shift with the advent of targeted therapies and novel drug development. For patients with advanced, inoperable, or metastatic MTC, traditional chemotherapy and radiotherapy offer limited efficacy, prompting a search for more effective systemic treatments. Tyrosine kinase inhibitors (TKIs) such as vandetanib and cabozantinib have emerged as the frontline therapies in such cases, particularly for patients with progressive disease. These agents work by inhibiting RET and other pathways involved in tumor growth and angiogenesis, offering prolonged progression-free survival and disease control. More recently, highly selective RET inhibitors like selpercatinib and pralsetinib have demonstrated significant clinical benefits with fewer off-target effects, especially in patients with RET-mutant tumors. These drugs represent a significant advancement in precision oncology, as they allow clinicians to match treatment with a patient’s specific genetic alterations. Ongoing clinical trials are exploring combination therapies, immunotherapies, and other novel agents aimed at overcoming resistance to current treatments. Despite these advances, treatment side effects and the risk of eventual disease progression remain challenges, necessitating continuous monitoring and adjustment of therapeutic strategies. Additionally, access to these therapies can vary based on healthcare infrastructure and insurance coverage, influencing outcomes in different regions. As research continues to expand the arsenal of targeted treatments, the outlook for patients with advanced MTC is improving, though long-term management still requires a careful balance of efficacy, safety, and quality of life considerations.

What Are the Key Drivers Fueling Growth and Innovation in the Medullary Thyroid Cancer Market?

The growth in the medullary thyroid cancer market is driven by several intersecting forces related to diagnostic innovation, drug development, patient awareness, and healthcare infrastructure expansion. First, increased use of routine neck ultrasounds and fine-needle aspiration biopsies has led to earlier detection of thyroid nodules, some of which are identified as MTC through follow-up molecular and biochemical testing. Second, rising awareness of genetic syndromes like MEN 2 among physicians and the public has led to greater demand for genetic counseling and early screening in high-risk families. Third, ongoing advances in genomics and precision medicine are fueling the development of targeted therapies that improve survival outcomes and offer new hope to patients with advanced disease. Fourth, investment by pharmaceutical companies in orphan drug development is incentivizing research and commercialization of therapies for rare cancers like MTC, resulting in a more robust treatment pipeline. Fifth, the proliferation of digital health tools and patient advocacy platforms is enabling individuals to access second opinions, participate in clinical trials, and better manage their care. Sixth, expanding access to healthcare in emerging economies is gradually improving diagnosis and treatment rates, although disparities still exist. Seventh, regulatory support through fast-track designations and orphan drug approvals is accelerating the time to market for new treatments. Lastly, multidisciplinary care models integrating endocrinology, oncology, genetics, and surgery are enhancing patient outcomes through coordinated and comprehensive care. These drivers collectively support a growing and increasingly sophisticated market focused on improving diagnosis, treatment, and quality of life for patients affected by medullary thyroid cancer.

SCOPE OF STUDY:

The report analyzes the Medullary Thyroid Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Chemotherapy Treatment); End-Use (Hospitals End-Use, Radiation Therapy Center End-Use, Cancer Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â